Immunology
News
FDA pulls U.S. authorization for Eli Lilly’s COVID drug bebtelovimab
The drug is not expected to neutralize the dominant BQ.1 and BQ.1.1 subvariants of Omicron.
Latest News
How can clinicians distinguish food allergy and GERD in young kids?
“Many allergists fear that patients may be labeled with a food allergy unnecessarily. Because no biomarkers or tests for food allergy–related GERD...
Feature
Buzzy Lancet long COVID paper under investigation for ‘data errors’
A reader found inconsistencies between the data in the article and a later paper describing the same cohort of patients after a year of follow-up...
Feature
Covid vax prevents death in children regardless of variant
But the vaccine’s effectiveness decreased over time.
Feature
More vaccinated people dying of COVID as fewer get booster shots
But the case for the effectiveness of vaccines and boosters versus skipping the shots remains strong.
From the Journals
Add tezepelumab to SCIT to improve cat allergy symptoms?
“Tezepelumab is currently an expensive biologic, so it remains to be seen whether patients and payors will be willing to pay for this add-on...
Latest News
Experts explain the ‘perfect storm’ of rampant RSV and flu
“Decreased exposure to endemic viruses created an immunity gap – a group of susceptible individuals who avoided infection and therefore lack...
Latest News
Birth method affects microbiome and vaccination response
Babies born vaginally have a different microbiome to those born by Caesarean section and have heightened responses to childhood vaccinations.
Feature
Doctors urge screening for autoimmune disorders for patients with celiac disease
At least in some cases, people with one autoimmune disorder should be tested for others, celiac disease specialists say.
Conference Coverage
Infant anaphylaxis: Study characterizes symptoms, treatment
It also remains vitally important “to teach parents of infants how to recognize the signs of anaphylaxis, particularly as they begin to introduce...
Latest News
COVID bivalent booster better vs. recent Omicron subvariants: Pfizer
An ongoing phase 2 trail shows the vaccine offered the strongest protection in people older than 55 years.